Multiplex Real-Time Polymerase Chain Reaction-Based Method for the Rapid Detection of gyrA and parC Mutations in Quinolone-Resistant Escherichia coli and Shigella spp

Osong Public Health and Research Perspectives

Volumn 3, Issue 2, 2012, Pages 113-117

  Kim, Junyoung ^a   Jeon, Semi ^a   Kim, Hyungjun ^a   Park, Misun ^a   Kim, Soobok ^b   Kim, Seonghan ^a  

^a Korea National Institute of Health   (South Korea)

^b Kogene Biotech   (South Korea)

Author keywords

Fluoroquinolone; GyrA; Multiplex real time PCR; ParC

Indexed keywords

DNA TOPOISOMERASE (ATP HYDROLYSING) A; PROTEIN PARC; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM ISOLATE; CODON; ESCHERICHIA COLI; GENE MUTATION; INFECTION CONTROL; MULTIPLEX POLYMERASE CHAIN REACTION; NONHUMAN; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SHIGELLA;

EID: 84862657349     PISSN: 22109099     EISSN: 22109110     Source Type: Journal    
DOI: 10.1016/j.phrp.2012.04.004     Document Type: Article

References (14)

1. Hooper D.C. New uses for new and old quinolones and the challenge of resistance. Clin Infect Dis 2000, 30:243-254.
2. Nakamura S. Mechanism of quinolone resistance. J Infect Chemother 1997, 3:128-138.
3. Lautenbach E., Strom B.L., Nachamkin I., et al. Longitudinal Trends in fluoroquinolone resistance among Enterobacteriaceae isolates from inpatients and outpatients, 1989-2000: differences in the emergence and epidemiology of resistance across organisms. Clin Infect Dis 2004, 38:655-662.
4. Uchida Y., Mochimaru T., Morokuma Y., et al. Geographic distribution of fluoroquinolone-resistant Escherichia coli strains in Asia. Int J Antimicrob Agents 2010, 35:358-373.
5. Drlica K., Zhao X. DNA gyrase, topoisomerase IV, and the 4-quionoloe. Microbiol Mol Biol Rev 1997, 61:377-392.
6. Ruiz J., Gomez J., Navia M.M., et al. High prevalence of nalidixic acid resistant ciprofloxacin susceptible phenotype among clinical isolates of Escherichia coli and other Enterobacteriaceae. Diag Microbiol Infect Diseases 2002, 42:257-261.
7. Jung D., Lee M., Kim J., et al. Isolation of quinolone-resistant Escherichia coli found in major rivers in Korea. J Microbiol. 2006, 44:680-684.
8. Kim J., Kim S., Jeon S., et al. Resistance to fluoroquinolones by the combination of target site mutations and enhanced expression of genes for efflux pumps in Shigella flexneri and Shigella sonnei strains isolated in Korea. Clin Microbiol Infect 2008, 14:760-765.
9. Heaton V.J., Ambler J.E., Fisher L.M. Potent antipneumococcal activity of gemifloxacin is associated with dual targeting of gyrase and topoisomerase IV, an in vivo target preference for gyrase, and enhanced stabilization of cleavable complexes in vitro. Antimicrob Agents Chemother 2000, 44:3112-3117.
10. Rodrigo A., Estibaliz M., Romon C. Detection of parC mutation in Streptococcus pneumonia by real-time PCR and Taqman-MGB probes. J Microbiol Method 2007, 69:214-217.
11. Lysnyansky I., Mikula I., Gerchman I., Levisohn S. Rapid detection of a point mutation in the parC gene associated with decreased susceptibility to fluoroquinolones in Mycoplasma bovis. Antimicrob Agents Chemother 2009, 53:4911-4914.
12. Page S., Vernel P.F., O'Conneor O., et al. Real-time PCR detection of gyrA and parC mutation in Streptococcus pneumonia. Antimicrob Agents Chemother 2008, 52:4155-4158.
13. Deborah J.E., Ernesto L., Martin J.W., Laura J.P. Detection gyrA mutations in quinolone-resistant Salmonella enteric by denaturin high-peformance liquid chromatography. J Clin Microbiol. 2002, 40:4121-4125.
14. Giraud E., Brisabois A., Martel J.L., Chaslus D.E. Comparative studies of mutations in animal isolates and experimental in vitro and in vivo-selected mutants of Salmonella spp. suggest a counter selection of highly fluoroquinolone-resistant strains in the field. Antimicrob Agents Chemother 1999, 43:2131-2137.